In particular, the Class IIa HDAC4 is overexpressed in EOC and is correlated to poor overall survival and/or unfavorable progress-free survival in all ovarian cancer patients (n > 1400) examined [37,38]. Here, HDAC4 is linked to ovarian cancer.